Back to Newsroom

Cempra Initiates Solithromycin Pediatric Program

First Patient Dosed in Biomedical Advanced Research and Development Authority (BARDA)-Funded Phase 1 Study

CHAPEL HILL, N.C., Feb. 20, 2014 — Cempra, Inc. (Nasdaq:CEMP) today announced the dosing of the first patient in its Phase 1 study of solithromycin capsules in children. The clinical trial is funded through Cempra’s contract with the Biomedical Advanced Research and Development Authority (BARDA; http://www.phe.gov/about/barda/Pages/default.aspx).